Skip to main content

Research Repository

Advanced Search

Outputs (16)

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Jones, C. (2024). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey (2023)
Journal Article
Prior, J. A., Roddy, E., Solis-Trapala, I., Cornwall, N., Jinks, C., Abhishek, A., …Hider, S. (in press). How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey. Rheumatology Advances in Practice, 7(3), Article rkad102. https://doi.org/10.1093/rap/rkad102

Analgesic Prescribing in Patients with Inflammatory Arthritis in England: Observational Studies in the Clinical Practice Research Datalink (2023)
Journal Article
Scott, I. C., Jordan, K. P., Twohig, H., Whittle, R., Muller, S., Hider, S. L., …Bailey, J. (2023). Analgesic Prescribing in Patients with Inflammatory Arthritis in England: Observational Studies in the Clinical Practice Research Datalink. Rheumatology, Article kead463. https://doi.org/10.1093/rheumatology/kead463

Despite little evidence that analgesics are effective in inflammatory arthritis (IA), studies report substantial opioid prescribing. The extent this applies to other analgesics is uncertain. We undertook a comprehensive evaluation of analgesic prescr... Read More about Analgesic Prescribing in Patients with Inflammatory Arthritis in England: Observational Studies in the Clinical Practice Research Datalink.

Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review (2023)
Journal Article
Mudge, H. R., Honey, J. R., Tachoukaft, S., Hider, S. L., Mason, K. J., Welsh, V. K., & Burton, C. (in press). Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review. Arthritis Care & Research, 76(1), 40-48. https://doi.org/10.1002/acr.25227

Musculoskeletal symptoms are commonly reported following acute coronavirus disease 2019 (COVID‐19). It is unclear whether those with musculoskeletal symptoms subsequently develop inflammatory rheumatic musculoskeletal disease (iRMD). This review seek... Read More about Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review.

Incorporating FRAX into a nurse-delivered integrated care review: a multi-method qualitative study. (2023)
Journal Article
Hawarden, A., Bullock, L., Chew-Graham, C., Herron, D., Hider, S., Jinks, C., …Paskins, Z. (2023). Incorporating FRAX into a nurse-delivered integrated care review: a multi-method qualitative study. British Journal of General Practice Open (BJGP Open), 7(2), https://doi.org/10.3399/BJGPO.2022.0146

Background: People with inflammatory rheumatological conditions (IRCs) are at increased risk of common comorbidities including osteoporosis.

Aim: To explore the barriers to and facilitators of implementing nurse-delivered fracture risk assessments... Read More about Incorporating FRAX into a nurse-delivered integrated care review: a multi-method qualitative study..

OP0275-HPR ‘IT’S A LOT TO TAKE IN’: A SYSTEMATIC REVIEW OF THE INFORMATION NEEDS OF PEOPLE WITH INFLAMMATORY ARTHRITIS STARTING METHOTREXATE (2023)
Presentation / Conference
Logan, S., Hider, S., Green, J., & Ryan, S. (2023, May). OP0275-HPR ‘IT’S A LOT TO TAKE IN’: A SYSTEMATIC REVIEW OF THE INFORMATION NEEDS OF PEOPLE WITH INFLAMMATORY ARTHRITIS STARTING METHOTREXATE. Presented at EULAR 2023 European Congress of Rheumatology, Milan, Italy

Background Guidelines recommend that people with Inflammatory Arthritis have access to tailored information when starting treatment with Methotrexate (MTX) [1]. It is not known what information people with Inflammatory Arthritis (IA) need to take MTX... Read More about OP0275-HPR ‘IT’S A LOT TO TAKE IN’: A SYSTEMATIC REVIEW OF THE INFORMATION NEEDS OF PEOPLE WITH INFLAMMATORY ARTHRITIS STARTING METHOTREXATE.

AB1595 HOW DO WE PREVENT THE DEVELOPMENT OF MULTIMORBIDITY IN PEOPLE WITH INFLAMMATORY RHEUMATOLOGICAL DISORDERS: A QUALITATIVE INVESTIGATION (2023)
Journal Article
Grey, L., Bullock, L., Chew-Graham, C. A., Jinks, C., Paskins, Z., Rule, T., & Hider, S. (2023). AB1595 HOW DO WE PREVENT THE DEVELOPMENT OF MULTIMORBIDITY IN PEOPLE WITH INFLAMMATORY RHEUMATOLOGICAL DISORDERS: A QUALITATIVE INVESTIGATION. Annals of the Rheumatic Diseases, 82(Suppl 1), 2031 - 2031. https://doi.org/10.1136/annrheumdis-2023-eular.5564

Background: People with inflammatory rheumatological disorders (IRDs) are at high risk of developing multimorbidity, specifically cardiovascular disease (CVD) and mood problems. UK guidelines advocate annual reviews for people with Rheumatoid Arthrit... Read More about AB1595 HOW DO WE PREVENT THE DEVELOPMENT OF MULTIMORBIDITY IN PEOPLE WITH INFLAMMATORY RHEUMATOLOGICAL DISORDERS: A QUALITATIVE INVESTIGATION.

E047 I felt like I’d been given a new lease of life: Exploring the information needs and experiences of people with rheumatoid arthritis receiving bridging glucocorticoids when starting methotrexate (2023)
Presentation / Conference
Logan, S. J., Hider, S., Green, J., & Ryan, S. J. (2023, April). E047 I felt like I’d been given a new lease of life: Exploring the information needs and experiences of people with rheumatoid arthritis receiving bridging glucocorticoids when starting methotrexate. Poster presented at British Society for Rheumatology Annual Conference 2023, Manchester Central Convention Complex, Manchester, UK